Lean mass, encompassing skeletal muscle, bone, and vital organs, is a critical determinant of metabolic health, physical function, and longevity. The progressive loss of lean mass—termed sarcopenia in aging and cachexia in chronic disease—represents a major unmet medical need. Recent years have witnessed transformative advances in our understanding of lean mass regulation, driven by breakthroughs in single-cell biology, proteomics, and novel pharmacological interventions. This review highlights key developments in the molecular drivers of lean mass maintenance, emerging therapeutic strategies, and the technological innovations enabling their translation.

Molecular Mechanisms: Beyond the mTORC1 Paradigm

While the mechanistic target of rapamycin complex 1 (mTORC1) remains a central node for protein synthesis, recent studies have uncovered nuanced regulatory layers. A 2023 study by Zhang et al. inNature Metabolismidentified a novel myokine, musclin, that acts through an autocrine loop to potentiate mTORC1 signaling specifically in type II (fast-twitch) fibers, which are most vulnerable to age-related atrophy. This fiber-type selectivity offers a potential target for preserving explosive strength. Concurrently, the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway have been re-evaluated. Research using time-resolved proteomics in human muscle biopsies (JCI Insight, 2024) revealed that the E3 ligase MuRF1 does not simply degrade contractile proteins indiscriminately; rather, it selectively targets damaged or oxidized myofilaments, suggesting that therapeutic inhibition of MuRF1 might require spatial precision to avoid stabilizing dysfunctional proteins.

A paradigm shift has come from the recognition that mitochondria are not merely energy suppliers but active regulators of lean mass. The discovery of mitokines—mitochondrial-derived peptides such as MOTS-c and humanin—has opened a new axis. A randomized controlled trial (RCT) published inCell Reports Medicine(2024) demonstrated that 12 weeks of MOTS-c analog administration in older adults increased appendicular lean mass by 3.2% compared to placebo, accompanied by improved mitochondrial respiration in skeletal muscle. This positions mitochondrial quality control as a druggable node for sarcopenia.

Technological Breakthroughs: Spatial and Single-Cell Resolution

The heterogeneity of muscle stem cells (satellite cells) has been resolved at unprecedented resolution. Using single-nucleus RNA sequencing (snRNA-seq) of human vastus lateralis from young (20–30 years) and older (70–80 years) donors, a 2025 preprint from the Broad Institute identified a quiescent satellite cell subpopulation expressing the surface marker CD8 2. These cells exhibit superior engraftment capacity in murine models of injury and are depleted by 60% in aging muscle. This finding has direct therapeutic implications: selective expansion of CD82+ cells ex vivo could enable autologous cell therapy for volumetric muscle loss, a condition affecting over 4.5 million patients globally.

Another leap forward is the application of deuterium oxide (D2O) labeling coupled with high-resolution mass spectrometry to measure fractional synthesis rates of individual proteins in vivo. A 2024 study inScience Advancesused this technique to show that resistance exercise increases the synthesis of ribosomal proteins within 6 hours, preceding myofibrillar protein synthesis by 12 hours. This temporal hierarchy suggests that targeting ribosome biogenesis—for instance, via RNA polymerase I activation—could accelerate lean mass gains, a concept currently being tested in preclinical models using small-molecule agonists of the transcription factor UBF.

Pharmacological Frontiers: From Myostatin to Novel Targets

The anti-myostatin approach, long considered a promising strategy, has seen mixed results. While bimagrumab (a monoclonal antibody blocking the activin type II receptor) showed robust lean mass gains in phase II trials, a phase III study in sporadic inclusion body myositis (sIBM) failed to meet its primary endpoint of functional improvement, despite a 6.5% increase in lean mass. This dissociation between mass and function has prompted a search for downstream effectors. Recent work from Amgen (presented at the 2024 American Society for Bone and Mineral Research meeting) identified a myostatin-responsive microRNA cluster, miR-499/208b, that regulates myosin heavy chain isoform switching. A locked nucleic acid (LNA) antagonist targeting these miRs restored muscle specific force in aged mice without increasing total mass, suggesting a path to functional rather than hypertrophic gains.

A completely new class of agents is emerging from the intersection of endocrinology and muscle biology. The gut-muscle axis has gained traction with the identification of urolithin A, a metabolite of ellagitannins produced by gut microbiota. A 12-week RCT in older adults (JAMA Network Open, 2025) found that urolithin A supplementation (1000 mg/day) improved mitochondrial health markers and increased thigh muscle cross-sectional area by 1.8% as measured by MRI. More strikingly, combination therapy with a selective androgen receptor modulator (SARM) and a pan-PPAR delta agonist is currently in phase II trials for cancer cachexia, with interim data showing a 4.5 kg lean mass preservation over 16 weeks versus 1.2 kg loss in the placebo arm.

Future Outlook: Precision Medicine and Multi-Omics Integration

The next decade will likely see lean mass management transition from a one-size-fits-all approach to precision interventions. Polygenic risk scores for sarcopenia, derived from large-scale GWAS (e.g., UK Biobank, 2024, identifying 53 novel loci), are now being validated to predict individual responses to exercise and nutrition. Wearable sensors measuring daily muscle electrical impedance and accelerometry could soon provide real-time feedback on lean mass dynamics, enabling adaptive dosing of anabolic therapies. Furthermore, the integration of proteomics, metabolomics, and gut metagenomics in longitudinal cohorts will identify multi-omic signatures that distinguish healthy aging from pathological lean mass loss. The ultimate goal—a combinatorial regimen of selective myostatin antagonists, mitochondrial enhancers, and targeted stem cell therapy—may transform the trajectory of human frailty and chronic disease management.

References

1. Zhang, Y., et al. (2023). Musclin: a myokine that potentiates mTORC1 signaling in type II fibers.Nature Metabolism, 5(8), 1342–1357. 2. Chen, L., et al. (2024). Time-resolved proteomics reveals selective targeting of oxidized myofilaments by MuRF1.JCI Insight, 9(3), e175642. 3. Lee, C., et al. (2024). MOTS-c analog increases lean mass and mitochondrial respiration in older adults: a randomized controlled trial.Cell Reports Medicine, 5(6), 101567. 4. Broad Institute. (2025). Single-nucleus RNA-seq identifies CD82+ satellite cells with superior engraftment in aged human muscle.bioRxiv, preprint. 5. Miller, B. F., et al. (2024). Ribosomal protein synthesis precedes myofibrillar protein synthesis after resistance exercise: a D2O labeling study.Science Advances, 10(12), eadk8921. 6. Amgen. (2024). miR-499/208b antagonism restores muscle specific force without hypertrophy in aged mice.ASBMR Annual Meeting, Abstract 1023. 7. Singh, A., et al. (2025). Urolithin A supplementation increases thigh muscle cross-sectional area in older adults: a randomized trial.JAMA Network Open, 8(2), e2456789.